Dr. Agarwal's Eye Hospital Limited (DRAGARWQ) Fair Value & Analysis
Healthcare · IN · Market cap ₹24.3B
Fair value as of: Jul 5, 2026
From 24 valuation models · updated today
Share price −1.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹4,304 – ₹5,759 · fair‑value band ₹1,706 – ₹5,084 · the ₹5,033 price screens above the ₹2,901 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Dr. Agarwal's Eye Hospital Limited (DRAGARWQ) currently trades at ₹5,033, while our model-based Fair Value estimate is ₹2,901 — implying the stock looks roughly 42.4% overvalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Dr. Agarwal's Eye Hospital Limited generated revenue of ₹4.7B at a net margin of 14.9%. Revenue grew 20.2% year over year. It earns a return on equity of 25.2%. Net debt stands at ₹752M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹1,706 (bear case) to ₹5,084 (bull case); at ₹5,033, the current price sits within that range. The share trades about 21% below its 52-week high and 19% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -32% fair-value upside — at -42%, DRAGARWQ screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Dr. Agarwal's Eye Hospital Limited engages in the provision of eye care and related services in India, Ghana, Uganda, Kenya, Madagascar, Tanzania, Rwanda, Zambia, Mozambique, and Mauritius. The company, through its hospitals, offers services in the areas of cataract, glaucoma, laser correction, cornea and refractive, retina, squint, keratitis, diabetic retinopathy, retinal detachment, nystagmus, ptosis, conjunctivitis, retinopathy prematurity, macular hole and edema, cornea transplantation, behcets, computer vision syndrome, hypertensive retinopathy, black fungus, traumatic cataract, keratoconus, uveitis, pterygium, blepharitis, posterior subcapsular cataract, rosette cataract, and congenital glaucoma. Dr. Agarwal's Eye Hospital Limited was founded in 1957 and is based in Chennai, India. Dr. Agarwal's Eye Hospital Limited operates as a subsidiary of Dr. Agarwal's Health Care Limited.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Dr. Agarwal's Eye Hospital Limited reported revenue of ₹4.7B in FY2026 versus ₹2.0B in FY2022, a compound +23.7%/yr. Reported net income was ₹701M in FY2026, compounding +30.6%/yr from FY2022.
Is DRAGARWQ fairly valued? → Check now
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.47 | $8.55 | -25% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
| Tenet Healthcare Corporation THC | $162.06 | $282.55 | +74% |
| Fresenius Medical Care AG FMS | $23.59 | $34.71 | +47% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,469 | ₹2,967 | -65% |
| DaVita Inc DVAI34 | R$1,081 | R$207.69 | -81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Dr. Agarwal's Eye Hospital Limited (DRAGARWQ) undervalued?
What is the fair value of DRAGARWQ?
What is the quality score of DRAGARWQ?
What is the revenue of Dr. Agarwal's Eye Hospital Limited (DRAGARWQ)?
What is the net profit margin of DRAGARWQ?
Does Dr. Agarwal's Eye Hospital Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.